A Single-Arm, Multicenter, Phase 2 Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate (MRG002) in HER2-Positive Unresectable Locally Advanced or Metastatic Urothelial Carcinoma

MRG002 is a novel HER2-targeted antibody-drug conjugate being investigated in the MRG002-006 trial to evaluate the efficacy and safety in HER2-positive urothelial carcinoma patients.

Source: European Journal of Cancer - May 9, 2024 Category: Cancer & Oncology Authors: Wang Qu, Cheng Fu, Weiqing Han, Hong Luo, Jizhong Quan, Lijun Chen, Yong Liao, Changlu Hu, Hailong Hu, Yinong Niu, Danfeng Xu, Minfeng Chen, Jimin Chen, Yongda Liu, Guojun Chen, Zhanxiong Luo, Benkang Shi, Yongkun Sun, Fangjian Zhou, Aiping Zhou Tags: Original Research Source Type: research